Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 109.0 | 79 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 117.0 | 99 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 297.0 | 81 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 419.0 | 77 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 295.0 | 62 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 154.0 | 83 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 237.0 | 81 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | MIP-1B | 230.0 | 79 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 99.0 | 63 | |
RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 103.0 | 74 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 82.0 | 85 | |
N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 100.0 | 84 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 93.0 | 101 | |
RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 95.0 | 113 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 82.0 | 83 | |
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 94.0 | 103 | |
RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 112.0 | 73 | |
RA1869 | TNF-a | 100 | ng/mL | 3 | MIP-1B | 103.0 | 52 | ||||
N2759 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 129.0 | 80 | |
N2759 | TNF-a | 100 | ng/mL | 3 | MIP-1B | 122.0 | 82 | ||||
RA1931 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 109.0 | 81 | |
RA1931 | TNF-a | 100 | ng/mL | 3 | MIP-1B | 116.0 | 77 | ||||
N2586 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | MIP-1B | 133.5 | 74 | |
N2586 | TNF-a | 100 | ng/mL | 3 | MIP-1B | 156.0 | 64 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | 3 | MIP-1B | 62.0 | 57 |